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Introduction
The role of positron emission tomography/computed tomography (PET/CT) in oncology imaging is rapidly expanding in clinical practice worldwide, due to increased clinical demand driven by greater availability of cyclotrons and automated chemistry synthesis modules for the production of radiopharmaceuticals. The added value of metabolic imaging over conventional imaging lies in its ability to evaluate specific metabolic pathways, providing semiquantitative measurements of tumor biology; nuclear medicine physicians and referring clinicians are living in wait for the introduction of new PET radiopharmaceuticals for routine clinical use. Most imaging studies are performed using 18 F-FDG PET, which is a highly sensitive and quite specific tracer for many entities. 18 F-FDG remains difficult to beat. However, because 18 F-FDG is not without its limitations, efforts have been made to study new tracers such as 3 0 -deoxy-3 0 -18-fluorothymidine ( 18 F-FLT). Cell proliferation is a pivotal aspect of tumor development and growth and is therefore a main target of cancer imaging. Cell proliferation can be assessed by a number of in vitro assays, which require tissue from biopsies; understanding of the molecular biology of cancer has conventionally been based on assays of tissue or blood samples. However, biopsies can be difficult to obtain, and they may not be representative of the proliferative activity of the whole tumor. As a consequence, imaging biomarkers have been explored as surrogates for these measurements, offering two main advantages: (1) whole-tumor and whole-body evaluation and (2) a non-invasive assessment. Even though 18 F-FDG has a wide field of application, some malignant tumors such as prostate cancer, neuroendocrine tumors, and hepatic tumors often fail to show significant uptake and may therefore go undetected. Moreover, 18 F-FDG presents two major drawbacks in oncology: it is not useful for evaluating malignancies in tissues with physiologically high glycolytic metabolism such as central nervous system tissues, and it cannot distinguish between inflammation and cancer, as both are characterized by increased glucose consumption. 18 F-FLT is a fluorinated tracer which has been proposed as an imaging biomarker of cell proliferation; in fact, during the S phase of the cell cycle, 18 F-FLT is phosphorylated by thymidinekinase-1 (TK-1) and trapped inside the cell, but not incorporated into the DNA, and thus provides an indirect measure of proliferation [1] . 18 F-FLT was originally produced after investigators discovered the anti-HIV properties of azidothymidine. In the initial phase I trial in patients with acquired immunodeficiency syndrome (AIDS), 3 0 -deoxy-3 0 -fluorothymidine (alovudine) was found to have higher toxicity at clinically useful doses [2] . These pharmacologic studies of unlabeled FLT, however, demonstrated that it can safely be given at the tracer doses used in PET. 18 F-FLT is transported into the cell in a manner similar to thymidine and then phosphorylated to 18 
F-FLT-5
0 -monophosphate and then further phosphorylated to FLT-triphosphate by the enzyme thymidylate kinase. FLT phosphates, however, are impermeable to the cell membrane and resistant to degradation and remain metabolically trapped inside the cells. The incorporation of FLT into DNA is less than 1 % [3] [4] [5] . Physiological uptake of the tracer is seen in the liver, bone marrow, and urinary tract, as it is renally excreted, while unlike 18 F-FDG, it shows no uptake in the brain, skeletal muscles, or myocardium. Variable uptake has been seen in normal gut [6, 7] . 18 F-FLT has been synthesized by radiofluorination of various precursors mainly using, as phase-transfer agents during nucleophilic substitution, Kryptofix 222, which provides reliable results and better yields but is difficult to eliminate and disruptive in the purification phase, and tetrabutylammonium hydrogen carbonate (TBA), which shows slightly inferior yields in terms of 18 F-Fluoride incorporation but is effectively retained by the strong cationic exchange resin during the purification step [8, 9] . The production of this radiopharmaceutical was first reported by Wilson et al. [10] . Machulla et al. [11] reported a simplified method for its synthesis, using 5 0 -O-(4,4 0 -dimethoxytriphenylmethyl)-2,3 0 -anhydrothymidine, and contemporaneously Grierson and Shields proposed a considerably improved method using 1-(2-deoxy-3-O-nosyl-5-O-DMT-b-D-threo-pentofuranosyl)-3-DMBn-thymine precursors [12] . Subsequently, further improved methods were proposed in the literature, often starting from new precursors; 3-N-boc-5 0 -O-DMTr-3 0 -Onosyl-lyxothymidine seemed to be the precursor affording the highest incorporation yields of [
18 F]-fluoride and therefore the most widely used [9] . Traditional synthesis of 18 F-FLT was associated with low labeling yields (5-20 %) and required difficult and time-consuming high-performance liquid chromatography (HPLC) purification to remove impurity products arising from the leaving group used in the precursor radiofluorination step or the blocking group in the hydrolysis step. Automated synthesis allowed production of 18 F-FLT in standardized and repeatable conditions, useful for obtaining clinical-grade 18 F-FLT [13] [14] [15] [16] [17] . Recently, some new methods allowing synthesis without HPLC purifications and using commercial synthesis modules have been proposed; these procedures reduce the synthesis time and in some cases improve the yield [9, 16, 17] . Many pre-clinical and early preliminary clinical studies were performed as a proof of concept mainly aimed at confirming the feasibility of this new imaging technique [3, [18] [19] [20] .
The aim of this review is to provide, through a comprehensive analysis of published data, an overall evaluation and description of the diagnostic role of 18 F-FLT PET or PET/CT in oncology imaging and clinical practice.
Methods
Search strategy
A comprehensive computer literature search of the PubMed/Medline databases was conducted to identify relevant published articles on the role of whole-body 18 F-FLT PET or PET/CT in oncology imaging and clinical practice. We used a search algorithm that was based on a combination of the terms: (a) '' 18 F-fluorothymidine'' OR ''3 0 -deoxy-3 0 -18-fluorothymidine'' OR ''FLT'' AND (b) ''positron emission tomography and positron emission tomography/computed tomography'' OR ''PET'' OR ''PET/CT''. No beginning date limit was used; the search was updated until August 2012. Only articles in English were selected.
Study selection and data abstraction
Studies investigating the diagnostic role of whole-body 18 F-FLT PET or PET/CT in clinical oncology were eligible for inclusion. Review articles, editorials, letters, case reports, conference proceedings, radiopharmaceutical kinetic, biodistribution and dosimetry analysis studies, and preclinical studies were excluded from this review. Only those studies including whole-body 18 F-FLT PET or PET/ CT scans performed in the diagnostic oncology setting were included. The titles and abstracts of the articles were reviewed applying the above-mentioned inclusion and exclusion criteria and rejected in the event of ineligibility. For each included study, information was collected concerning the basic study (author names, journal, year of publication, country of origin), the device used (PET or PET/CT), the tumor studied, and purpose of the imaging evaluation (diagnosis, staging, restaging, therapy response evaluation), the number of patients enrolled, and the main goals of the study. The main findings of the articles included in this review are reported in the results.
Results
Literature search
The comprehensive computer literature search of the PubMed/Medline databases revealed 371 articles. After reviewing the titles and abstracts, 217 articles were excluded because the reported data were not within the field of interest of this review, because they were preclinical studies, or because they were not in English; 58 articles were excluded because they were editorials or reviews; 10 articles were excluded because they were case reports (Fig. 1) . Finally, 86 articles were selected [6, 7, and retrieved in full-text version.
Literature data: report and discussion
The overall assessment of the published studies clearly shows heterogeneity both of the tumors analyzed and of the reasons for performing the evaluations (diagnosis, staging, restaging, and therapy response evaluation). All the retrieved papers were published in the period between 2003 and 2012. The tumor or organ most frequently analyzed was the lung (Table 1) , in 19 studies [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] ; the digestive tract (including the esophagus, stomach, colorectal tract, pancreas and liver; Table 2 ) was analyzed in 17 papers [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] , brain tumors (Table 3) in 15 [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] , head and neck tumors (Table 4) in nine [72] [73] [74] [75] [76] [77] [78] [79] [80] , myeloproliferative/ lymphoproliferative diseases (Table 5) in nine [6, 7, [81] [82] [83] [84] [85] [86] [87] , breast cancer (Table 6 ) in six [88] [89] [90] [91] [92] [93] , and all the others (including melanomas, sarcomas, ovarian cancer, uterine cancer, germ cell tumors, neuroendocrine tumors; Table 7 ) in 11 [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] . Twenty-four studies were performed in Germany, 15 in the United States, 14 in Japan, 13 in the Netherlands, six in China, five in the United Kingdom, four in South Korea, two in France, two in Austria, and one in India (Tables 1, 2 , 3, 4, 5, 6, 7). The number of patients enrolled in the studies was very low, ranging from five to 73; despite the low number of patients enrolled, almost all the studies were prospective (only two were retrospective). The injected activity ranged from 104 to 555 MBq, reaching an average of between 200 and 400 MBq; the waiting time after injection before imaging acquisition ranged from 30 to 120 min, but was most frequently in the range of 45-60 min.
Lung
Even though
18 F-FDG PET shows high sensitivity and good specificity in evaluating lung cancer and lung nodules and differentiating malignant from benign lesions, falsepositive results, mainly due to inflammation are still a problem. Consequently, a more specific tracer would be desirable and 18 F-FLT, which shows lower uptake in inflammatory tissues, has been proposed. Nineteen studies analyzed the role of 18 F-FLT PET or PET/CT in lung nodules or cancer, performed for different purposes: diagnosis, staging, restaging, and therapy response evaluation (Table 1) . Although many studies suggest a possible role for 18 F-FLT imaging in this field, on the basis of the biological added value of the technique, many others show its diagnostic performance to be lower than that of 18 18 F-FDG PET was false-negative in a carcinoma in situ, in a non-small-cell-lung-cancer (NSCLC) with a low proliferation index, and in a patient with lung metastases from colorectal cancer; on the other hand, increased uptake was related exclusively to malignant tumors. Cobben Table 2 Characteristics of the studies on the role of Table 3 Characteristics of the studies on the role of Hatakeyama et al. [63] 2008 Japan/P 18 F-FLT PET/ CT to assess early changes in uptake after gefitinib therapy; at 7 days after initiation, the percent changes in SUV max were significantly different, and a decrease of [10.9 % in SUV max was used as the criterion for predicting response. The positive and negative predictive values (PPV, NPV) were both 92.9 %, and 18 F-FLT PET/CT was judged useful in predicting therapy response. In the study by Everitt et al. [30] , in which five patients with locally advanced NSCLC underwent serial 18 F-FLT PET/CT scans during chemoradiotherapy (CMRT), it was found that 18 F-FLT uptake can monitor the distinctive biological responses of epithelial cancers and highly radiosensitive normal tissue changes. Kobe et al. [38] , Kahraman et al. [32] , and Zander et al. [37] analyzed, from different perspectives, a group of patients with untreated stage-IV NSCLC who, enrolled in a phase-II clinical trial, had undergone a combined 18 F-FDG PET and 18 F-FLT PET scan at 1 week and 6 weeks after erlotinib treatment. Kobe et al. [38] documented that early and late low residual 18 F-FDG and 18 F-FLT uptakes were associated with improved progression-free survival; residual 18 F-FLT uptake did not prove helpful for prediction of short-term outcome. Kahraman et al. [32] showed that early 18 F-FDG PET and 18 F-FLT PET can predict progression-free survival, but 18 F-FDG might be the most robust to use for early response prediction. Moreover, they showed that metabolically active volume measurement in early 18 F-FLT PET and late 18 F-FDG PET may have additional predictive value in monitoring response. Zander et al. [37] showed improved progression-free survival in patients with an early 18 F-FDG response followed by prolonged overall survival, but not in patients with an early 18 F-FLT response. In the study by Saga et al. [34] , 20 consecutive patients with lung cancer underwent 18 F-FLT PET/CT before and after carbon-ion radiotherapy (CIRT). Primary responses to CIRT were partial in 13 patients, stable disease in six patients, and non-evaluable in one patient. Kaplan-Meier analysis supported the prognostic value of pre-CIRT 18 PET/CT before surgery. Imaging correlated with tumor angiogenesis (fundamental in the growth, progression and metastases of solid tumors), as reflected by anti-CD105-mAb intratumoral microvessel density (CD105-MVD) immunohistochemical findings, and the authors suggested that it may be helpful in assessing antiangiogenic therapy. In the articles analyzed, 18 F-FLT PET was found to perform worse than 18 F-FDG when used for staging and restaging, but it seemed promising for therapy response evaluation in concordance with pathology findings.
Digestive tract
The digestive tract is an interesting diagnostic setting because is composed of many different organs (e.g., liver and colon) with different 18 F-FDG uptake patterns, which can sometimes affect diagnostic accuracy (especially in diabetic patients treated with oral hypoglycemic drugs).
Seventeen studies analyzed the role of 18 F-FLT PET or PET/CT in digestive tract cancers ( Table 2 ). The role of 18 F-FLT in colorectal cancer (CRC) imaging was analyzed in six studies. Francis et al. [40] prospectively studied 13 lesions from 10 patients with primary or recurrent CRC. Histology confirmed adenocarcinoma in 12/13 lesions. All eight extrahepatic lesions were visualized using 18 F-FLT PET correlated with cell proliferation markers in both primary and metastatic CRC and provided a mechanism for in vivo grading of malignancy. Moreover, Francis et al. [41] in the same year compared the cellular uptake of 18 F-FLT and 18 F-FDG in patients with CRC, analyzing 17 patients with 50 primary or metastatic lesions. All the primary tumors were visualized by both tracers, with 18 F-FDG showing on average twice the uptake of 18 F-FLT. Similar uptake of both tracers was seen in lung and peritoneal lesions. Of the 32 colorectal liver metastases, 11 (34 %) were seen to be avid for 18 F-FLT, compared with 31 (97 %) for 18 F-FDG. 18 F-FLT showed a high sensitivity in the detection of extrahepatic disease but a poor sensitivity for the imaging of colorectal liver metastases, limiting its role as a diagnostic tracer in CRC. Yamamoto et al. [49] 18 F-FDG and 18 F-FLT before and 2 weeks after initiation of chemotherapy in the study by Ott et al. [53] . 18 F-FLT uptake two weeks after initiation of therapy was shown to be the only imaging parameter with significant prognostic impact. In the study by Kameyama et al. [48] , 21 patients with newly diagnosed advanced GC were examined with 18 F-FLT PET and 18 F-FDG PET. The sensitivity of 18 F-FLT PET and 18 F-FDG PET for detection of advanced GC was 95.2 and 95.0 %, respectively. The sensitivity of 18 F-FLT PET was seen to be as high as that of 18 F-FDG PET for the detection of GC, although uptake was significantly lower.
The role of 18 F-FLT in esophageal cancer (EC) imaging has been analyzed in three articles. In the study by van Westreenen et al. [42] , 10 patients with cancer of the esophagus or gastroesophageal junction were staged with CT, endoscopic ultrasonography, and ultrasound of the neck. In addition, all patients underwent a whole-body 18 F-FLT PET and 18 F-FDG PET. 18 F-FDG PET was able to detect all EC, whereas 18 F-FLT-PET visualized the tumor in 8/10 patients. Both detected lymph-node metastases in 2/8 patients. 18 F-FDG PET detected one cervical lymph node that was missed on 18 F-FLT PET, whereas 18 F-FDG PET showed uptake in benign lesions in two patients. Uptake of 18 F-FDG in EC was significantly higher than that of 18 F-FLT, and the 18 F-FLT scans showed more falsenegative findings and fewer false-positive findings than the 18 18 F-FLT uptake that was higher than the surrounding background uptake (sensitivity 71.4 %).
18 F-FLT PET missed four well-differentiated and 2-T1 cancers. In the study by Quon et al. [46] , five patients with newly diagnosed and previously untreated pancreatic adenocarcinoma underwent 18 F-FLT PET/CT, 18 F-FDG PET/CT and contrast-enhanced CT before treatment. 18 F-FLT PET/CT showed poor lesion detectability and relatively low levels of radiotracer uptake in the primary tumor. Herrmann 18 F-FLT PET was performed in 18 untreated patients with liver lesions suspected to be hepatocellular carcinoma (HCC). HCC tumors showed a mixed uptake pattern for the in vivo proliferation marker 18 F-FLT. A total of 69 % of the HCC lesions showed 18 F-FLT uptake which was higher than that of the surrounding liver tissue, whereas the remaining lesions were photopenic or contained a mixture of hot and cold lesions. High initial 18 F-FLT uptake was associated with reduced overall survival.
In the articles analyzed, 18 F-FLT showed a lower falsepositive rate than 18 F-FDG and a potential usefulness, described in some papers, in histological types with low 18 F-FDG uptake. Despite this, 18 F-FLT PET did not record significantly better diagnostic performances than 18 F-FDG; in particular, it showed a poor ability to detect hepatic metastases.
Brain
As a consequence of its low background uptake in normal brain tissue, probably due to its low proliferation rate, 18 F-FLT has been proposed as an alternative to 18 F-FDG, which is instead characterized by high uptake, for the evaluation of brain tumors. The role of 18 F-FLT in brain tumor imaging was analyzed in 15 articles. Chen et al. [57] evaluated 25 patients with newly diagnosed or previously treated gliomas with both 18 F-FLT and 18 F-FDG. Three stable patients in long-term remission were included as negative control subjects and more than half of the patients underwent resection after the PET study to correlate uptake and the Ki-67 proliferation index. 18 F-FLT visualized all 18 high-grade tumors; low-grade tumors that did not show contrast enhancement on magnetic resonance (MR) with gadopentetate dimeglumine (Gd-DTPA) were not visualized; neither were all three stable lesions in patients in long-term remission; 18 F-FLT was 100 % sensitive and specific in all high-grade gliomas. Five patients with previously treated high-grade gliomas were considered stable on the basis of MR and clinical criteria before the PET study. 18 F-FLT PET studies were positive, while 18 F-FDG studies were negative, but all patients had tumor progression; 18 F-FLT appeared more accurate (sensitivity 100 %; specificity 100 %) in identifying recurrent high-grade glioma than 18 F-FDG (sensitivity 72 %; specificity 100 %). 18 F-FLT uptake correlated significantly better with the Ki-67 proliferation index than did 18 F-FDG; 18 F-FLT PET also had better prognostic power than 18 F-FDG to predict the time to tumor progression, as well as survival. In the study by Choi et al. [58] , 26 patients with brain tumors (n = 18) or non-tumorous lesions (n = 8) underwent 18 F-FDG PET and 18 F-FLT PET imaging. Among the 18 brain tumors, 18 F-FLT showed increased uptake in all 12 highgrade tumors but 18 F-FDG uptake was variable. In 22 brain lesions with similar or decreased uptake compared with normal gray matter on 18 F-FDG, the sensitivity and specificity of 18 F-FLT were 79 and 63 %, respectively. The uptake ratios of brain tumors on 18 F-FLT were significantly higher than the lesion-to-gray matter ratios and lesion-towhite matter ratios of 18 F-FDG uptake and differed significantly between high-and low-grade tumors. Moreover, 18 F-FLT uptake was significantly correlated with the Ki-67 proliferation index. These findings indicated that 18 F-FLT PET was useful for evaluating tumor grade and cell proliferation. It displayed a high sensitivity and good contrast in evaluating brain lesions that showed similar or decreased uptake compared with normal gray matter on 18 F-FDG. In the study by Tripathi et al. [65] , 15 patients (2 patients in remission as controls) with newly diagnosed or previously treated low-grade gliomas underwent 18 F-DOPA, 18 F-FDG, and 18 F-FLT PET/CT studies on consecutive days. 18 F-DOPA was positive in all primary and recurrent low-grade glioma cases and negative in the patients in remission. Tumor was visualized on 18 F-FDG in seven of the 13 cases, and on 18 F-FLT in four of the 13 cases.
18 F-DOPA scan was superior to both 18 F-FLT and 18 F-FDG for visualization of primary and recurrent low-grade gliomas. 18 F-FLT was not recommended for evaluation of recurrent lowgrade gliomas. Twenty patients with suspected recurrence on brain MR after surgical removal of the primary tumor were included in the study of Hong et al. [66] . Of 20 lesions, 15 were recurrences and 18 F-FLT PET showed a high diagnostic sensitivity (15/15) and a moderate specificity (3/5).
18 F-FDG PET showed moderate diagnostic sensitivity (11/15) and specificity (4/5). All the four recurrent tumors without 18 F-FDG uptake showed 18 F-FLT uptake. The authors demonstrated that 18 F-FLT PET had a higher sensitivity to detect a recurrent brain tumor due to the high contrast of tumor to normal tissue, but, due to the lower specificity, a limited value as a complementary tool to MR for differentiating recurrence from radiationinduced change; the possible explanation was that 18 F-FLT cannot be transported across intact blood-brain barrier (BBB), but can cross the disrupted BBB of not only neoplastic lesions but also inflammation or necrosis. In the study by Enslow et al. [67] , 15 patients with suspected recurrence of treated grade 2 glioma were studied with 18 F-FDG and 18 F-FLT PET. Both quantitative and visual determinations allowed accurate differentiation between recurrent glioma and radiation necrosis with both tracers. In the study by Jacobs et al. [59] , PET scanning was performed with 18 F-FLT and L-(S-methyl-[ 11 C])methionine, ([ 11 C]methionine) were performed on 23 patients with histologically verified gliomas of different grades. Uptake ratios of 18 F-FLT were higher than uptake ratios of 11 C-methionine, but the sensitivity for the detection of tumors was lower for 18 F-FLT than for 11 C-methionine (78.3 vs 91.3 %), especially for low-grade astrocytomas. Uptake ratios of 18 F-FLT were higher in glioblastomas than in astrocytomas. In the study by Hatakeyama et al. [63] , among 41 patients with newly diagnosed gliomas, 18 underwent both 11 C-methionine PET and 18 F-FLT PET. 11 C-methionine exhibited a slightly higher sensitivity (87.8 %) in tumor detection than 18 F-FLT (83.3 %). All tumors were graded by the WHO grading system using surgical specimens, and the proliferation activity was determined by measuring the Ki-67 index obtained by immunohistochemical staining. 18 F-FLT PET seemed superior in non-invasive tumor grading and assessment of proliferation activity. Ullrich et al. [64] evaluated 13 patients with newly diagnosed high-grade gliomas with 18 F-FLT PET and 11 C-methionine PET. They showed that 18 F-FLT uptake is useful for the in vivo assessment of tumor proliferation, whereas uptake ratios of 11 C-methionine and 18 F-FLT failed to correlate with the in vitro determined proliferation marker. Harris et al. [68] analyzed 21 patients with recurrent malignant gliomas who underwent bevacizumab treatment with 18 F-FLT and showed that its uptake may be a valuable imaging biomarker for predicting progression-free survival. In the study by Jeong et al. [69] , 20 patients with newly diagnosed gliomas were investigated with 18 F-FLT and 18 F-fluoroethyl-L-tyrosine ( 18 F-FET) PET before surgery. 18 F-FLT PET detected all 17 high-grade gliomas but did not detect all three lowgrade gliomas.
18 F-FET PET detected all 20 gliomas regardless of grading. Comparison with 18 F-FLT PET showed that 18 F-FET PET showed a higher sensitivity in the detection of gliomas, but it seemed that 18 F-FLT PET was better than 18 F-FET PET for non-invasive grading and for predicting the prognosis of newly diagnosed gliomas. Miyake et al. [70] studied 54 patients affected by gliomas with 18 F-FDG, 11 C-methionine, and 18 F-FLT. Among these 54 glioma cases, 11 C-methionine accumulation was observed in 51 cases (94.4 %), 18 F-FLT accumulation in 50 cases (92.6 %), and 18 F-FDG accumulation in 27 cases (50 %). The three cases without 11 C-methionine accumulation and the four cases without 18 F-FLT accumulation were grade-2 gliomas. All malignant gliomas (grades 3-4) showed accumulation in both studies.
Moreover, in the study by Saga et al. [60] , 18 F-FLT PET was performed in 25 patients with primary brain tumors and was found to be useful in evaluating the malignant grade and proliferation activity of these tumors; both SUV max and tumor-to-normal brain uptake ratios significantly correlated with the malignant grade of brain gliomas. However, benign lesions showing BBB disruption could not be distinguished from malignant tumors and their presence therefore needed careful evaluation. Yamamoto et al. [61] retrospectively investigated 10 patients with recurrent glioblastoma multiforme who underwent 18 F-FLT PET and Gd-DTPA MR.
18 F-FLT PET was useful for the detection of recurrent glioblastoma multiforme, but no clear relationship emerged between 18 F-FLT accumulation and Gd-DTPA enhancement. Twenty-one patients with recurrent high-grade gliomas treated with bevacizumab and irinotecan were studied by Chen et al. [62] . 18 F-FLT PET was performed within 1 week before the initiation of treatment, and at 1-2 and 6 weeks after start of treatment. Contrast and non-contrast brain MR images for treatment monitoring were acquired in all patients within 1 week before and at 6-week intervals after the start of treatment. A 6-month survival of 65 % for glioblastoma patients was seen, and multivariate analysis demonstrated that 18 F-FLT response was the most powerful independent predictor of survival among all variables tested (age, number of recurrences, number of prior treatments, tumor grade, dexamethasone treatment, and time from radiation therapy). Baseline 18 F-FLT SUVs were not predictive of patient survival and through receiver operating curve analysis, a metabolic response of greater than 25 % reduction in tumor uptake was found to be the threshold with best predictive power for overall survival. Metabolic response was more powerful in predicting overall survival than anatomical imaging. In the study by Schwarzenberg et al. [71] , 30 patients treated with bevacizumab combination therapy underwent 18 F-FLT PET immediately before and at 2 and 6 weeks after the start of treatment, and results were compared to MR. Changes in tumor uptake were highly predictive of progression-free and overall survival in patients with recurrent malignant glioma on bevacizumab therapy, and 18 F-FLT PET seemed more predictive of early treatment response than MR.
In the articles analyzed, 18 F-FLT PET showed diagnostic performances that were better than those of 18 F-FDG PET, but lower than those of studies performed with 11 C-methionine or 18 F-FET.
Head and neck
This is a very difficult and challenging area because of the anatomical and metabolic complexity of the structures present; moreover, the diagnostic setting is further complicated by a variety of significant anatomical and metabolic modifications occurring after surgery or radiotherapy, which are the main therapeutic tools. In this setting, 18 F-FDG shows limitations mainly due to functional activation of normal tissues and inflammation, and therefore, a tracer with fewer inflammatory pitfalls would be desirable.
The role of 18 F-FLT in head and neck tumor imaging was analyzed in nine articles. Cobben et al. [72] evaluated 11 patients diagnosed or strongly suspected of having recurrent laryngeal cancer (LC) and 10 patients with histologically proven primary LC; all patients were staged by endoscopy and CT, and then submitted to 18 F-FLT PET, 18 F-FDG PET, and biopsy of the larynx after imaging. 18 F-FDG PET and 18 F-FLT PET detected LC correctly in 15/17 patients. One lesion judged as positive on 18 F-FDG PET turned out to be normal tissue. Of two lesions judged positive on 18 F-FLT PET, one turned out to be inflammation and the other to be normal tissue. The authors concluded that the numbers of LCs detected with 18 F-FLT PET and 18 F-FDG PET were equal. In the study by Troost et al. [73] , 10 patients with newly diagnosed stage II-IV head and neck squamous cell cancers (HNSCCs) underwent 18 F-FLT PET to determine the lymph-node status. The sensitivity, specificity, PPV, and NPV were 100, 16.7, 37.5, and 100 %, respectively, due to the high rate of falsepositive findings. 18 F-FLT PET showed uptake in metastatic as well as in non-metastatic reactive lymph nodes. Because of the low specificity, 18 F-FLT PET was judged unsuitable for assessment of pre-treatment lymph-node status. In the study by Linecker et al. [74] , 20 patients with previously untreated lesions of the head and neck underwent PET scans with 18 F-FLT and 18 F-FDG, a CT and a biopsy. Nineteen patients had malignant tumors, and one a benign cystadenoma of the parotid gland. The sensitivity was 95 % for both tracers. A significant correlation between both PET tracers and survival was detected, but no correlation between the amount of Ki-67 positive cells and 18 F-FLT, showing that the tracer does not provide additional visual information in comparison to 18 F-FDG. Been et al. [75] evaluated 14 patients with LC who underwent both 18 F-FLT PET and 18 F-FDG PET. They concluded that 18 F-FLT PET was feasible in visualizing LC; the overall uptake was significantly lower as compared with 18 F-FDG, but tumor-to-background ratios were comparable. In the study by Troost et al. [76] , 10 patients with oropharyngeal tumor underwent an 18 F-FLT PET/CT scan before and in the second and fourth weeks of RT. All primary tumors and lymph-node metastases were visualized. In the primary tumors, the SUV max of the second 18 F-FLT PET scan was already significantly decreased relative to the first scan, and the SUV max of the third scan was decreased even further. This study showed that 18 F-FLT PET signal changes precede volumetric tumor response and that the tracer is therefore suitable for early response assessment. Troost et al. [77] aimed to validate 18 F-FLT PET in squamous cell carcinomas of the oral cavity using immunohistochemical staining for the proliferation marker iododeoxyuridine and for TK-1. Seventeen patients underwent an 18 F-FLT PET/ CT scan before surgery. All primary tumors were identified but with a large range in tracer uptake; there emerged only a weak correlation between 18 F-FLT uptake and iododeoxyuridine staining intensity in oral cavity tumors. Hoshikawa et al. [78] F-FDG. The specificity and overall AC of 18 F-FLT were significantly higher than those of 18 F-FDG both during and after radiotherapy and had the potential to predict therapeutic response and identify patients needing close follow-up to detect persistent or recurrent disease.
In the articles analyzed, despite the low number of studies available, 18 F-FLT PET showed good diagnostic performances compared to 18 F-FDG in the absence of a documented superiority; the added value seemed to concern therapy response evaluation.
Lympho-myeloproliferative diseases
One of the most well-established diagnostic applications of 18 F-FDG in oncology is its use in the evaluation of lymphoproliferative diseases, especially Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL); consequently, a new tracer would really have to be more accurate than 18 F-FDG before replacing it.
The role of 18 F-FLT in the imaging of lympho-myeloproliferative diseases was analyzed in nine articles. Even though Agool et al.
[81] demonstrated low 18 F-FLT uptake in 18 patients affected by myeloproliferative disorders, Buchmann et al. [6] showed that the use of 18 F-FLT is feasible in NHL imaging and Buck et al. [7] showed it to offer advantages for the detection of lymphoma in the central nervous system in 34 patients, due to negligible background uptake of 18 F-FLT in the brain. In the study by Herrmann et In the articles analyzed, 18 F-FLT PET did not seem able to replace 18 F-FDG; given the negligible background uptake in the brain, a possible added value might be gained in detection of lymphoma in the central nervous system, which seemed to be an appropriate field of application.
Breast
The role of 18 18 F-FLT PET to assess therapy response after chemotherapy and showed that it can detect changes in breast cancer proliferation at 1 week after 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy. Contractor et al. [92] evaluated 20 patients who underwent a baseline dynamic 18 F-FLT PET scan followed by a similar post-treatment scan conducted approximately 14 days after the first or second cycle of docetaxel therapy; they showed that 18 F-FLT PET was a promising imaging biomarker to detect early response. Moreover, Contractor et al. [93] performed a small pilot study to compare early changes in levels of circulatory tumor cells (CTCs) with changes in tumor proliferation, using imaging with 18 F-FLT in women with advanced breast cancer, before and during docetaxel therapy. In those individuals in whom they detected CTCs, a decrease in CTC count correlated with a decrease in 18 F-FLT signal, within 2 weeks.
In these very few articles analyzed, 18 F-FLT PET seemed to be interesting mainly for therapy response evaluation.
Miscellanea
The remaining 11 articles evaluated the use of 18 F-FLT PET in various tumors not belonging to the above groups. Dittmann et al. [95] reported a high sensitivity in 16 patients with thoracic tumors (8 lung, 5 esophageal, 2 sarcoma and 1 Hodgkin's lymphoma). Cobben et al. [96] evaluated 19 patients with soft-tissue sarcoma (STS), identifying 20 tumors clearly visible with high contrast and reporting a sensitivity of 100 %. Been et al. [97] evaluated 10 patients with primary non-resectable STS of an extremity documenting high 18 F-FLT uptake which was correlated with the mitotic index. In the study by Buck et al. [98] , 18 F-FLT PET was performed in 22 patients with established or suspected soft or bone tissue lesions;
18 F-FDG PET was performed in 15 patients. 18 F-FLT PET detected all malignant bone or soft tissue tumors and correlated significantly with the tumor grade while 18 F-FDG did not. 18 F-FLT was judged superior for non-invasive grading of sarcomas. In the study by Benz et al. [103] , 20 patients with biopsy-proven high-grade STS underwent 18 F-FLT PET/CT imaging before and after neoadjuvant therapy. Marked reductions in 18 F-FLT tumor uptake in response to neoadjuvant treatment were observed in most patients, but these reductions were not specific for histopathologic response to neoadjuvant therapy. Furthermore, post-treatment 18 18 F-FLT in either the primary or the metastatic tumor site, whatever the status of patients; this finding, probably a reflection of the slow proliferation rate of tumors, suggests that 18 F-FLT was not a suitable tracer.
Conclusions
In conclusion, no high quality evidence could be derived on the role of 18 F-FLT PET in oncology imaging because of the extreme heterogeneity between the studies (with regard to the tumors evaluated, the reasons for performing the evaluations, and the devices and methodologies used), the limited number of studies for each tumor, and the very low number of patients enrolled in each study. Despite these limitations, this comprehensive review of the literature reveals published results which suggest that this tracer has a promising role in oncology imaging, especially in (1) assessing response to treatment or therapy monitoring. Since no uptake or lower uptake than other tracers (especially 18 F-FDG) is expected in inflammatory cells, 18 F-FLT could be very useful for therapy response evaluation allowing earlier identification of non-responders who could be switched to second-line treatment; in this scenario, it represents a highly promising method contributing to the individualization of cancer therapy; (2) tumor grading. 18 F-FLT can be seen as a proliferation tracer because it is phosphorylated by TK-1 which is commonly higher in malignant lesions making it more tumor-specific than other tracers; moreover, the strong correlations between 18 F-FLT uptake and histopathological proliferation markers can serve as a non-invasive tool for establishing tumor grade; (3) evaluating brain malignancies. In this setting, the low background uptake, probably due to the slow proliferation rate of normal tissue, is an advantage even though it will be difficult for this tracer to beat 18 F-FET and 18 F-DOPA. Further studies are needed to confirm these preliminary results, and larger trials are desirable to establish the definitive diagnostic role of 18 F-FLT in oncological clinical practice, considering, its usefulness in relation to and in comparison with the well-established 18 F-FDG, its importance in terms of cost-effectiveness and its correct position in the diagnostic flow-chart for each tumor type. 
